Rosie is a life sciences specialist with experience in prosecuting patent applications in a wide range of technologies including DNA sequencing, biofuels, antibodies, microbiology, pharmaceutics, assay technologies, immunology and oil recovery.
Rosie has advised universities, multinationals and SMEs on all stages of the patent process, from patentability to grant and has gained experience in all aspects of patent drafting and prosecution having spent four years at another IP firm prior to joining EIP.
Rosie has a degree in biochemistry from the University of Edinburgh. She then attended Queens University Belfast where she completed a PhD in biochemistry at the Centre for Vision and Vascular Sciences. Her research centred on investigating the reasons underlying protein adduct accumulation in the diabetic retina.
- Secondment to the in-house patent department of a large multinational client.
- December 2019
Lawyer Monthly, Should you be able to patent genes? (link)
- 13 November 2019
Health Europa, Gene patent reform in the US and the knock-on effect in Europe (link)
- 15 August 2018
Diabetologia, Müller glial dysfunction during diabetic retinopathy in rats is reduced by the acrolein-scavenging drug, 2-hydrazino-4,6-dimethylpyrimidine (link)
- September 2016
IOVS, Diabetes impairs the aldehyde detoxifying capacity of the retina (link)
- 30 January 2013
Future Medicinal Chemistry, The therapeutic potential for targeting lipid aldehydes and advanced lipoxidation end products in ocular disease (link)
Education and qualifications
UK Patent Attorney, 2018
European Patent Attorney, 2018
PGCert Intellectual Property Law, Brunel University
2010 — 2013
PhD in Biochemistry, Queens University Belfast
2006 — 2009
BSc Biochemistry, University of Edinburgh
- 2017 — present
- 2013 — 2017
Technical Assistant (Life Sciences), Dehns